A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients

被引:68
作者
Kiev, A
Feiger, A
机构
[1] Social Psychiatry Research Institute, New York, NY
[2] Social Psychiatry Research Institute, New York, NY 10021
关键词
D O I
10.4088/JCP.v58n0402
中图分类号
B849 [应用心理学];
学科分类号
040203 ;
摘要
Background: Fluvoxamine and paroxetine, both serotonin selective reuptake inhibitors (SSRIs), were compared at two centers in a 7-week double-blind study in outpatients with major depression, diagnosed by DSM-III-R criteria. Method: Sixty patients were randomly assigned to receive dosage titrated upward to between 50-150 mg/day of fluvoxamine (N = 30) or 20-50 mg/day of paroxetine (N = 30). The mean +/- SD daily dose administered at the last assessment was 102 +/- 44 mg/day for fluvoxamine and 36 +/- 13 mg/day for paroxetine. Sixteen (53%) fluvoxamine-treated patients and 10 (33%) paroxetine-treated patients were titrated to the maximum permissible dosage of either drug. Sample size was calculated to provide at least 85% power at 5% level of significance to detect at least a 1.00-point difference in mean severity of adverse events, assuming a standard deviation of 1.0. Results: Fluvoxamine and paroxetine were similarly effective in ameliorating depression as demonstrated by mean total scores of 10.9 +/- 7.3 (p < .00) and 11.5 +/- 7.4 (p < .00), respectively, in the Hamilton Rating Scale for Depression (HAM-D). Adverse events were mostly mild to moderate in severity. The most common events were headache (N = 17, 57%), nausea (N = 14, 47%), sweating (N = 10, 33%), somnolence (N = 9, 30%), diarrhea (N = 9, 30%), dry mouth (N = 8, 27%), dizziness (N = 8, 27%), and, among males, impotence (N = 3, 21%) and ejaculatory abnormality (N = 3, 21%) in the paroxetine group, and headache (N = 12, 40%), somnolence (N = 12, 40%), nausea (N = 11, 37%), dry mouth (N = 11, 37%), insomnia (N = 9, 30%), asthenia (N = 7, 23%), and dyspepsia (N = 7, 23%) in the fluvoxamine group. The only statistically significant difference between treatment groups was for sweating (33% paroxetine vs. 10% fluvoxamine, p = .028). Conclusion: Observed differences in some side effects, although not statistically significant, indicate that when a patient has difficulty tolerating one SSRI, the clinician may choose to change to a different agent within the same class.
引用
收藏
页码:146 / 152
页数:7
相关论文
共 30 条
  • [1] *AM PSYCH ASS, 1987, DIAGN STAT MAN MENT, P245
  • [2] BROWN WA, 1992, PSYCHOPHARMACOL BULL, V28, P253
  • [3] CLAASEN V, 1983, BR J CLIN PHARM S3, V15, pS49
  • [4] FLUVOXAMINE, A SPECIFIC 5-HYDROXYTRYPTAMINE UPTAKE INHIBITOR
    CLAASSEN, V
    DAVIES, JE
    HERTTING, G
    PLACHETA, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1977, 60 (04) : 505 - 516
  • [5] CONTI L, 1988, CURR THER RES CLIN E, V43, P468
  • [6] *COSTART, 1989, COD SYMB THES ADV RE
  • [7] FLUVOXAMINE MALEATE - DISPOSITION IN MAN
    DEBREE, H
    VANDERSCHOOT, JB
    POST, LC
    [J]. EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1983, 8 (02) : 175 - 179
  • [8] EFFICACY OF FLUVOXAMINE IN TREATMENT-REFRACTORY DEPRESSION
    DELGADO, PL
    PRICE, LH
    CHARNEY, DS
    HENINGER, GR
    [J]. JOURNAL OF AFFECTIVE DISORDERS, 1988, 15 (01) : 55 - 60
  • [9] HOPKINS SYMPTOM CHECKLIST (HSCL) - SELF-REPORT SYMPTOM INVENTORY
    DEROGATIS, LR
    LIPMAN, RS
    RICKELS, K
    UHLENHUTH, EH
    COVI, L
    [J]. BEHAVIORAL SCIENCE, 1974, 19 (01): : 1 - 15
  • [10] DEWILDE J, 1993, HOSP FORMUL, V28, P36